TransCode Therapeutics, Inc.
RNAZ
$1.77
-$0.13-6.61%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 53.23% | 133.46% | 21.33% | 49.26% | -18.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.59% | 131.10% | 42.16% | 110.64% | -17.46% |
| Operating Income | -47.59% | -131.10% | -42.16% | -110.64% | 17.46% |
| Income Before Tax | -57.83% | -45.25% | -123.41% | -109.19% | 17.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.84% | -47.16% | -127.23% | -109.19% | 17.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.84% | -47.16% | -127.23% | -109.19% | 17.61% |
| EBIT | -47.59% | -131.10% | -42.16% | -110.64% | 17.46% |
| EBITDA | -47.49% | -131.33% | -41.57% | -111.98% | 17.20% |
| EPS Basic | -39.81% | 69.67% | 94.14% | 96.01% | -- |
| Normalized Basic EPS | -32.85% | 88.74% | 97.65% | 96.01% | -- |
| EPS Diluted | -39.81% | 69.67% | 94.14% | 96.01% | -- |
| Normalized Diluted EPS | -32.85% | 88.74% | 97.65% | 96.01% | -- |
| Average Basic Shares Outstanding | 14.81% | 432.21% | 4,227.49% | 5,143.40% | -- |
| Average Diluted Shares Outstanding | 14.81% | 432.21% | 4,227.49% | 5,143.40% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |